web monitor

Collagen Type II, Chicken, Soluble

chicken collagen type II (CII)
Catalog Number: 
804002-sol
Qty/Size: 
5 mL

chicken collagen type II (CII) from MD Bioproducts

North America: 1-888-USMDBIO
International: +41-44 986 2628

Or you can order by using our online form
Have questions or need bulk? No problem, just ask.

Collagen type II (CII) protein, purified from chicken sternum, for the induction of arthritis in the Collagen-Induced Arthritis (CIA) model.

Overview

Overview: 

Type II collagen (CII) is a fibrillar collagen that is primarily located in cartilage tissue. The major molecular form of collagen in cartilage is type II collagen. Type II collagen is also located in the vitreous humor of the eye, the inner ear, the nose, and the intervertebral discs of the spine. The function of type II collagen is to provide tensile strength and give cartilage the ability to resist shearing forces. Mutations of the COL2A1 gene affect the synthesis of type II collagen and cause chondrodysplasias. This is characterized by abnormal cartilage that leads to bone and joint deformities. The degradation of collagen type II is an early indicator of osteoarthritis.

 

Type II Collagen and Adjuvent Susceptibility to CIA is linked to MHC class II molecules and is dependent upon the species of type II collagen used for immunization. Various species of highly purified Type II Collagen are supplied lyophilized and in solution for use in the induction of arthritis in vivo.

 

Symbols/Related Terms:

 

  • COL2A1
  • pro-alpha 1(II) chain
  • Achondrogenesis
  • Hypochondrogenesis
  • Spondyloepiphyseal dysplasia
  • Osteoarthritis (OA)
  • Collagen Induced Arthritis (CIA)

 

Data/Specifications

Data/Specifications: 

Concentration: 10 mg

Purity:  >99% as determined by SDS-PAGE and visualized by Coomassie blue staining

Purification:  Differential salt precipitation

Source:  chick sternum 

Form:  Lyophilized 

Literature/Support

Literature/Support: 

Chicken Collagen Type II Insert (PDF)

 

Moschovakis, G. L., Bubke, A., Friedrichsen, M., Ristenpart, J., Back, J. W., Falk, C. S., ... & Förster, R. (2018). The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy. Cellular & molecular immunology


Vierboom, M. P., Breedveld, E., Keehnen, M., Klomp, R., & Bakker, J. (2017). Pain Relief in Nonhuman Primate Models of Arthritis. In Inflammation (pp. 411-417). Humana Press, New York, NY

 

Kurowska-Stolarska, M., Alivernini, S., Melchor, E. G., Elmesmari, A., Tolusso, B., Tange, C., ... & Stewart, L. (2017). MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature communications8, 15877.

 

Moschovakis, G. L., Bubke, A., Friedrichsen, M., Falk, C. S., Feederle, R., & Förster, R. (2017). T cell specific Cxcr5 deficiency prevents rheumatoid arthritis. Scientific Reports7(1), 8933.

 

Verheul, M. K., Vierboom, M. P., Bert, A., Toes, R. E., & Trouw, L. A. (2017). Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis. Arthritis research & therapy19(1), 246.

 

Athari, S. K., Poirier, E., Biton, J., Semerano, L., Hervé, R., Raffaillac, A., ... & Boissier, M. C. (2016). Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33. Arthritis research & therapy18(1), 143.

 

Biton, J., Athari, S. K., Thiolat, A., Santinon, F., Lemeiter, D., Hervé, R., ... & Girard, J. P. (2016). In vivo expansion of activated Foxp3+ regulatory T cells and establishment of a type 2 immune response upon IL-33 treatment protect against experimental arthritis. The Journal of Immunology, 1502124.

 

Vierboom, M. P. M., Breedveld, E., Kap, Y. S., Mary, C., Poirier, N., 't Hart, B. A., & Vanhove, B. (2016). Clinical efficacy of a new CD28‐targeting antagonist of T cell co‐stimulation in a non‐human primate model of collagen‐induced arthritis. Clinical & Experimental Immunology183(3), 405-418.

 

Van Roy, M., Ververken, C., Beirnaert, E., Hoefman, S., Kolkman, J., Vierboom, M., ... & Jacobs, S. (2015). The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis research & therapy17(1), 135.

 

Vicente, R., Quentin, J., Mausset-Bonnefont, A. L., Chuchana, P., Martire, D., Cren, M., ... & Louis-Plence, P. (2015). Nonclassical CD4+ CD49b+ regulatory T cells as a better alternative to conventional CD4+ CD25+ T cells to dampen arthritis severity. The Journal of Immunology, 1501069.

 

Perez, J., Dansou, B., Hervé, R., Levi, C., Tamouza, H., Vandermeersch, S., ... & Boissier, M. C. (2015). Calpains released by T lymphocytes cleave TLR2 to control IL-17 expression. The Journal of Immunology, 1500749.

 

Lindh, I., Snir, O., Lönnblom, E., Uysal, H., Andersson, I., Nandakumar, K. S., ... & Holmdahl, R. (2014). Type II collagen antibody response is enriched in the synovial fluid of rheumatoid joints and directed to the same major epitopes as in collagen induced arthritis in primates and mice. Arthritis research & therapy16(4), R143.

 

Roy, L. D., Sahraei, M., Schettini, J. L., Gruber, H. E., Besmer, D. M., & Mukherjee, P. (2014). Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC cancer, 14(1), 225.

 

Chen, Y. M., Chuang, H. C., Lin, W. C., Tsai, C. Y., Wu, C. W., Gong, N. R., ... & Chen, D. Y. (2013). Germinal Center Kinase–like Kinase Overexpression in T Cells as a Novel Biomarker in Rheumatoid Arthritis. Arthritis & Rheumatism, 65(10), 2573-2582.

 

Marenzana, M., Vugler, A., Moore, A., & Robinson, M. (2013). Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study. Arthritis Res Ther, 15(5), R125.

 

Iqbal, A. J., Cooper, D., Vugler, A., Gittens, B. R., Moore, A., & Perretti, M. (2013). Endogenous galectin-1 exerts tonic inhibition on experimental arthritis. The Journal of Immunology, 191(1), 171-177.

 

Vierboom, M., Breedveld, E., Kondova, I., & 't Hart, B. (2010). Collagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritis. Arthritis Research and Therapy, 12(5), R200.

 

Asquith, D. L., Miller, A. M., Hueber, A. J., Liew, F. Y., Sattar, N., & McInnes, I. B. (2010). Apolipoprotein E–deficient mice are resistant to the development of collagen‐induced arthritis. Arthritis & Rheumatism, 62(2), 472-477.

 

Pufe, T., Petersen, W., Kurz, B., Tsokos, M., Tillmann, B., & Mentlein, R. (2003). Mechanical factors influence the expression of endostatin—an inhibitor of angiogenesis—in tendons. Journal of orthopaedic research21(4), 610-616.

 

Bäcklund, J., Treschow, A., Bockermann, R., Holm, B., Holm, L., Issazadeh‐Navikas, S., ... & Holmdahl, R. (2002). Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen‐induced arthritis. European journal of immunology32(12), 3776-3784.

 

References/Citations:How the Chicken Collagen Type II protein was used:
Apolipoprotein E-deficient mice are resistant to the development of collagen-induced arthritis.
Asquith DL, Miller AM, et al. Arthritis Rheum. 2010 Feb; 62(2):472-7.
Induce arthritis in C57BL/6 WT or ApoE(-/-) mice at 12 weeks of age. On day 0, mice were injected intradermally with 200 μg of type II chicken collagen with CFA. On day 21, a booster of type II chicken collage/PBS (200 μg) was injected intraperitoneally.
Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Van Beneden K, et al. Annals of the rheumatic diseases. 2009; 68(8):1360-5.Induce arthritis in DBA/1 mice. A 100 uL emulsion was used for induction and animals were challenged with a secondary injection of CII in incomplete Freund adjuvant 21 days later.


 

How To Use

How To Use: 

Applications

 

  • Induction of arthritis in vivo
  • Cell Culture
  • ELISA standard/plate coating